Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 43157M102 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
EcoR1 Capital, LLC
13G/A
Amendment 1
|
0% |
11/14/2025
Event 9/30/2025
|
|
| EcoR1 Capital, LLC | 0% | ||
| Oleg Nodelman | 0% | ||
| EcoR1 Capital Fund Qualified, L.P. | 0% | ||
|
Takeda Pharmaceutical Co Ltd
13D/A
Amendment 1
|
0% |
9/19/2025
Event 9/17/2025
|
|
| Takeda Pharmaceutical Company Limited | 0% | ||
| Takeda Vaccines Inc. | 0% | ||
|
Tang Capital Management LLC
13D/A
Amendment 1
|
0% |
9/19/2025
Event 9/17/2025
|
|
| Tang Capital Management, LLC | 0% | ||
| Kevin Tang | 0% | ||
| Tang Capital Partners, LP | 0% | ||
| Tang Capital Partners International, LP | 0% | ||
| Tang Capital Partners III, Inc | 0% | ||
| Tang Capital Partners IV, Inc | 0% | ||
| Concentra Biosciences, LLC | 0% | ||
|
Frazier Life Sciences Public Fund, L.P.
13D/A
Amendment 5
|
0% |
9/17/2025
Event 9/17/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 0% | ||
| FHMLSP, L.P. | 0% | ||
| FHMLSP, L.L.C. | 0% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 0% | ||
| FHMLSP Overage, L.P. | 0% | ||
| FHMLSP Overage, L.L.C. | 0% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences XI, L.P. | 0% | ||
| FHMLS XI, L.P. | 0% | ||
| FHMLS XI, L.L.C. | 0% | ||
| James N. Topper | 0% | ||
| Patrick J. Heron | 0% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
|
EcoR1 Capital, LLC
13G
|
5.8% |
7/24/2025
Event 7/17/2025
|
|
| EcoR1 Capital, LLC | 5.8% | ||
| Oleg Nodelman | 5.8% | ||
| EcoR1 Capital Fund Qualified, L.P. | 5.4% | ||
|
Tang Capital Management LLC
13D
|
9.8% |
5/2/2025
Event 5/2/2025
|
|
| Tang Capital Management, LLC | 9.8% | ||
| Kevin Tang | 9.8% | ||
| Tang Capital Partners, LP | 5.5% | ||
| Tang Capital Partners International, LP | 4.3% | ||
| Tang Capital Partners III, Inc | 0% | ||
| Tang Capital Partners IV, Inc | 0% | ||
| Concentra Biosciences, LLC | 0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q3 | 1 | 179 k | $0 |
| 2025 Q2 | 78 | 41.6 M | $82.6 M |
| 2025 Q1 | 82 | 42.2 M | $61.5 M |
| 2024 Q4 | 77 | 42.8 M | $88.7 M |
| 2024 Q3 | 81 | 41.8 M | $73.5 M |
| 2024 Q2 | 99 | 45.6 M | $659 M |
| 2024 Q1 | 85 | 44.1 M | $733 M |
| 2023 Q4 | 73 | 42.8 M | $686 M |
| 2023 Q3 | 69 | 34.1 M | $459 M |
| 2023 Q2 | 55 | 25.4 M | $437 M |
| 2023 Q1 | 64 | 26.4 M | $436 M |
| 2022 Q4 | 57 | 26.6 M | $445 M |
| 2022 Q3 | 52 | 23.4 M | $400 M |
| 2022 Q2 | 58 | 23.2 M | $254 M |